Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 a.m. EST. The presentation will be accessible via a live and archived webcast on the company’s investors webpage.

Pulmonx is recognized for its innovative solutions for severe lung disease, notably the Zephyr® Endobronchial Valve, which has received FDA pre-market approval. The valve is currently available in over 25 countries, having been used in more than 25,000 patients worldwide.

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming 40^th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 11, 2022, at 7:30 a.m. Eastern Standard Time.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

What event is Pulmonx Corporation participating in January 2022?

Pulmonx Corporation will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022.

What time is Pulmonx's presentation at the conference?

Pulmonx's management is scheduled to present at 7:30 a.m. Eastern Standard Time.

How can I watch Pulmonx's presentation?

The presentation will be available via a live and archived webcast on Pulmonx's investors webpage.

What is the significance of the Zephyr Valve from Pulmonx?

The Zephyr Valve is a minimally invasive treatment for severe emphysema/COPD and has received FDA pre-market approval as a breakthrough device.

Where is the Zephyr Valve available?

The Zephyr Valve is commercially available in over 25 countries.

How many patients have been treated with the Zephyr Valve?

Over 25,000 patients have been treated with the Zephyr Valve.